{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T19:25:01Z","timestamp":1770665101385,"version":"3.49.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14227-4","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T06:26:24Z","timestamp":1746771984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhenpo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yankun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qimin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chufeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"issue":"5","key":"14227_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"issue":"4","key":"14227_CR2","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985\u20131005. https:\/\/doi.org\/10.1038\/s41375-020-0734-z.","journal-title":"Leukemia"},{"issue":"2","key":"14227_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325\u201332. https:\/\/doi.org\/10.1038\/s41591-021-01622-0.","journal-title":"Nat Med"},{"issue":"1","key":"14227_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of Axicabtagene Ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7.","journal-title":"Lancet Oncol"},{"issue":"10254","key":"14227_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene Maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0.","journal-title":"Lancet"},{"issue":"14","key":"14227_CR6","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell therapy in relapsed or refractory Mantle-Cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1914347.","journal-title":"N Engl J Med"},{"issue":"8","key":"14227_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"issue":"6","key":"14227_CR8","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023;41(6):1265\u201374. https:\/\/doi.org\/10.1200\/JCO.22.00842.","journal-title":"J Clin Oncol"},{"issue":"4","key":"14227_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7. Published 2021 Apr 6.","journal-title":"Blood Cancer J"},{"issue":"10","key":"14227_CR10","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transpl. 2019;54(10):1643\u201350. https:\/\/doi.org\/10.1038\/s41409-019-0487-3.","journal-title":"Bone Marrow Transpl"},{"key":"14227_CR11","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;13:927153. https:\/\/doi.org\/10.3389\/fimmu.2022.927153. Published 2022 Jun 10.","journal-title":"Front Immunol"},{"issue":"13","key":"14227_CR12","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","volume":"4","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn K, Pennisi M, Garcia-Recio M, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 2020;4(13):3024\u201333. https:\/\/doi.org\/10.1182\/bloodadvances.2020001972.","journal-title":"Blood Adv"},{"issue":"9967","key":"14227_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(14)61403-3.","journal-title":"Lancet"},{"issue":"4","key":"14227_CR14","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3324\/haematol.2019.238634","volume":"106","author":"JM Logue","year":"2021","unstructured":"Logue JM, Zucchetti E, Bachmeier CA, et al. Immune reconstitution and associated infections following Axicabtagene Ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021;106(4):978\u201386. https:\/\/doi.org\/10.3324\/haematol.2019.238634. Published 2021 Apr 1.","journal-title":"Haematologica"},{"issue":"9","key":"14227_CR15","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.bbmt.2020.04.025","volume":"26","author":"ML Schubert","year":"2020","unstructured":"Schubert ML, Dietrich S, Stilgenbauer S, et al. Feasibility and safety of CD19 chimeric antigen receptor T cell treatment for B cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2020;26(9):1575\u201380. https:\/\/doi.org\/10.1016\/j.bbmt.2020.04.025.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"14227_CR16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ajh.26486","volume":"97","author":"X Shi","year":"2022","unstructured":"Shi X, Yan L, Shang J, et al. Anti-CD19 and anti-BCMA CAR T cell therapy followed by Lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. Am J Hematol. 2022;97(5):537\u201347. https:\/\/doi.org\/10.1002\/ajh.26486.","journal-title":"Am J Hematol"},{"issue":"8","key":"14227_CR17","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.3324\/haematol.2022.281455","volume":"108","author":"Z Song","year":"2023","unstructured":"Song Z, Tu D, Tang G, et al. Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy. Haematologica. 2023;108(8):2067\u201379. https:\/\/doi.org\/10.3324\/haematol.2022.281455. Published 2023 Aug 1.","journal-title":"Haematologica"},{"issue":"8","key":"14227_CR18","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","volume":"45","author":"M Fusaroli","year":"2022","unstructured":"Fusaroli M, Isgr\u00f2 V, Cutroneo PM, et al. Post-Marketing surveillance of CAR-T-Cell therapies: analysis of the FDA adverse event reporting system (FAERS) database. Drug Saf. 2022;45(8):891\u2013908. https:\/\/doi.org\/10.1007\/s40264-022-01194-z.","journal-title":"Drug Saf"},{"issue":"13","key":"14227_CR19","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1080\/10428194.2023.2254430","volume":"64","author":"A Gomez-Lumbreras","year":"2023","unstructured":"Gomez-Lumbreras A, Mercadal Vilchez S, Villa-Zapata L, Malone DC, Couriel DR. Chimeric antigen receptor T-cell immunotherapies adverse events reported to FAERS database: focus on cytopenias. Leuk Lymphoma. 2023;64(13):2071\u201380. https:\/\/doi.org\/10.1080\/10428194.2023.2254430.","journal-title":"Leuk Lymphoma"},{"key":"14227_CR20","unstructured":"U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract Files. 2023. https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html. Accessed 30 May 2024."},{"issue":"5","key":"14227_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster O, Aoki Y, Gattepaille LM, Grundmark B. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting False-Positive associations. Drug Saf. 2020;43(5):479\u201387. https:\/\/doi.org\/10.1007\/s40264-020-00911-w.","journal-title":"Drug Saf"},{"issue":"5","key":"14227_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","volume":"15","author":"PS Ang","year":"2016","unstructured":"Ang PS, Chen Z, Chan CL, Tai BC. Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures. Expert Opin Drug Saf. 2016;15(5):583\u201390. https:\/\/doi.org\/10.1517\/14740338.2016.1167184.","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"14227_CR23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1517\/14740338.2014.915938","volume":"13","author":"Y Hou","year":"2014","unstructured":"Hou Y, Ye X, Wu G, Cheng G, Du X, He J. A comparison of disproportionality analysis methods in National adverse drug reaction databases of China. Expert Opin Drug Saf. 2014;13(7):853\u20137. https:\/\/doi.org\/10.1517\/14740338.2014.915938.","journal-title":"Expert Opin Drug Saf"},{"key":"14227_CR24","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","volume":"59","author":"C Zhou","year":"2023","unstructured":"Zhou C, Peng S, Lin A, et al. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. EClinicalMedicine. 2023;59:101967. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101967. Published 2023 Apr 21.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"14227_CR25","doi-asserted-by":"publisher","first-page":"e001511","DOI":"10.1136\/jitc-2020-001511","volume":"8","author":"MV Maus","year":"2020","unstructured":"Maus MV, Alexander S, Bishop MR, et al. Society for immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020;8(2):e001511. https:\/\/doi.org\/10.1136\/jitc-2020-001511.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"14227_CR26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12885-021-09102-x","volume":"22","author":"W Luo","year":"2022","unstructured":"Luo W, Li C, Zhang Y, et al. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis. BMC Cancer. 2022;22(1):98. https:\/\/doi.org\/10.1186\/s12885-021-09102-x. Published 2022 Jan 24.","journal-title":"BMC Cancer"},{"issue":"18","key":"14227_CR27","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1817226.","journal-title":"N Engl J Med"},{"issue":"8","key":"14227_CR28","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.7150\/ijms.46811","volume":"18","author":"Q Yang","year":"2021","unstructured":"Yang Q, Li X, Zhang F, Yang Q, Zhou W, Liu J. Efficacy and safety of CAR-T therapy for relapse or refractory multiple myeloma: A systematic review and meta-analysis. Int J Med Sci. 2021;18(8):1786\u201397. https:\/\/doi.org\/10.7150\/ijms.46811. Published 2021 Feb 18.","journal-title":"Int J Med Sci"},{"issue":"1","key":"14227_CR29","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1080\/07853890.2022.2136748","volume":"54","author":"Y Xia","year":"2022","unstructured":"Xia Y, Zhang J, Li J, et al. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors. Ann Med. 2022;54(1):2951\u201365. https:\/\/doi.org\/10.1080\/07853890.2022.2136748.","journal-title":"Ann Med"},{"issue":"Supplement 1","key":"14227_CR30","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1182\/blood-2022-165646","volume":"140","author":"S Thibaud","year":"2022","unstructured":"Thibaud S, Mia M, Van Oekelen O, et al. Comprehensive characterization of prolonged unexplained cytopenias in relapsed\/refractory multiple myeloma patients following BCMA-Directed CAR-T cell therapy. Blood. 2022;140(Supplement 1):614\u20136. https:\/\/doi.org\/10.1182\/blood-2022-165646.","journal-title":"Blood"},{"issue":"10","key":"14227_CR31","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, et al. A real-world comparison of tisagenlecleucel and Axicabtagene Ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28(10):2145\u201354. https:\/\/doi.org\/10.1038\/s41591-022-01969-y.","journal-title":"Nat Med"},{"issue":"1","key":"14227_CR32","doi-asserted-by":"crossref","first-page":"77e","DOI":"10.1016\/j.jtct.2023.10.017","volume":"30","author":"CA Jacobson","year":"2024","unstructured":"Jacobson CA, Munoz J, Sun F, et al. Real-World outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: A systematic review and Meta-Analysis. Transpl Cell Ther. 2024;30(1):77e. 1-77.e15.","journal-title":"Transpl Cell Ther"},{"key":"14227_CR33","doi-asserted-by":"publisher","unstructured":"Li Y, Ming Y, Fu R et al. The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Front Pharmacol. 2022;13:950923. Published 2022 Oct 14. https:\/\/doi.org\/10.3389\/fphar.2022.950923","DOI":"10.3389\/fphar.2022.950923"},{"issue":"1","key":"14227_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med"},{"issue":"1","key":"14227_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34\u201348. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.478.","journal-title":"Ann Oncol"},{"issue":"10","key":"14227_CR36","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Somerville RP, Shi V, et al. Allogeneic T cells that express an Anti-CD19 chimeric antigen receptor induce remissions of B-Cell malignancies that progress after allogeneic hematopoietic Stem-Cell transplantation without causing Graft-Versus-Host disease. J Clin Oncol. 2016;34(10):1112\u201321. https:\/\/doi.org\/10.1200\/JCO.2015.64.5929.","journal-title":"J Clin Oncol"},{"issue":"24","key":"14227_CR37","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021;138(24):2499\u2013513. https:\/\/doi.org\/10.1182\/blood.2020010543.","journal-title":"Blood"},{"key":"14227_CR38","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","volume":"11","author":"RD Sandler","year":"2020","unstructured":"Sandler RD, Tattersall RS, Schoemans H, et al. Diagnosis and management of secondary HLH\/MAS following HSCT and CAR-T cell therapy in adults; A review of the literature and a survey of practice within EBMT centres on behalf of the autoimmune diseases working party (ADWP) and transplant complications working party (TCWP). Front Immunol. 2020;11:524. https:\/\/doi.org\/10.3389\/fimmu.2020.00524. Published 2020 Mar 31.","journal-title":"Front Immunol"},{"key":"14227_CR39","doi-asserted-by":"publisher","unstructured":"Rejeski K, Kunz WG, Rudelius M et al. Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report. BMC Infect Dis. 2021;21(1):121. Published 2021 Jan 28. https:\/\/doi.org\/10.1186\/s12879-020-05755-4","DOI":"10.1186\/s12879-020-05755-4"},{"key":"14227_CR40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13073-015-0244-1","volume":"7","author":"B Tesi","year":"2015","unstructured":"Tesi B, Lagerstedt-Robinson K, Chiang SC, et al. Targeted high-throughput sequencing for genetic diagnostics of hemophagocytic lymphohistiocytosis. Genome Med. 2015;7:130. https:\/\/doi.org\/10.1186\/s13073-015-0244-1. Published 2015 Dec 18.","journal-title":"Genome Med"},{"key":"14227_CR41","doi-asserted-by":"publisher","first-page":"101719","DOI":"10.1016\/j.trim.2022.101719","volume":"75","author":"I Cutini","year":"2022","unstructured":"Cutini I, Puccini B, Fabbri A, et al. Late haemophagocytic lymphohistiocytosis in a patient treated with Axicabtagene Ciloleucel. Transpl Immunol. 2022;75:101719. https:\/\/doi.org\/10.1016\/j.trim.2022.101719.","journal-title":"Transpl Immunol"},{"issue":"5","key":"14227_CR42","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","volume":"26","author":"Y Wang","year":"2020","unstructured":"Wang Y, Qi K, Cheng H, et al. Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies. Biol Blood Marrow Transpl. 2020;26(5):865\u201375. https:\/\/doi.org\/10.1016\/j.bbmt.2019.11.027.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"20","key":"14227_CR43","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood.2022017415","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023;141(20):2460\u20139. https:\/\/doi.org\/10.1182\/blood.2022017415.","journal-title":"Blood"},{"key":"14227_CR44","doi-asserted-by":"publisher","unstructured":"Wesson W, Dima D, Suleman N, et al. Timing of toxicities and Non-relapse mortality following CAR T therapy in myeloma. Transpl Cell Ther Published Online June. 2024;11. https:\/\/doi.org\/10.1016\/j.jtct.2024.06.012.","DOI":"10.1016\/j.jtct.2024.06.012"},{"issue":"2","key":"14227_CR45","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bjh.16623","volume":"191","author":"J Wang","year":"2020","unstructured":"Wang J, Mou N, Yang Z, et al. Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory\/relapsed B acute lymphoblastic leukaemia. Br J Haematol. 2020;191(2):212\u201322. https:\/\/doi.org\/10.1111\/bjh.16623.","journal-title":"Br J Haematol"},{"key":"14227_CR46","doi-asserted-by":"publisher","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study [published correction appears in lancet. 2021;398(10307):1216. Doi: 10.1016\/S0140-6736(21)02132-2]. Lancet. 2021;398(10297):314\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8.","DOI":"10.1016\/S0140-6736(21)00933-8"},{"issue":"9","key":"14227_CR47","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian S, Kramer AM, Onuoha S, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25(9):1408\u201314. https:\/\/doi.org\/10.1038\/s41591-019-0549-5.","journal-title":"Nat Med"},{"issue":"355","key":"14227_CR48","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8\u2009+\u2009and CD4\u2009+\u2009CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116. https:\/\/doi.org\/10.1126\/scitranslmed.aaf8621.","journal-title":"Sci Transl Med"},{"issue":"2","key":"14227_CR49","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","volume":"155","author":"Y Wang","year":"2014","unstructured":"Wang Y, Zhang WY, Han QW, et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol. 2014;155(2):160\u201375. https:\/\/doi.org\/10.1016\/j.clim.2014.10.002.","journal-title":"Clin Immunol"},{"issue":"7","key":"14227_CR50","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","volume":"98","author":"H Jiang","year":"2019","unstructured":"Jiang H, Liu L, Guo T, Wu Y, Ai L, Deng J, et al. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Ann Hematol. 2019;98(7):1721\u201332. https:\/\/doi.org\/10.1007\/s00277-019-03685-z.","journal-title":"Ann Hematol"},{"issue":"4","key":"14227_CR51","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/hon.3155","volume":"41","author":"R Liu","year":"2023","unstructured":"Liu R, Lv Y, Hong F, et al. A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2. Hematol Oncol. 2023;41(4):704\u201317. https:\/\/doi.org\/10.1002\/hon.3155.","journal-title":"Hematol Oncol"},{"issue":"3","key":"14227_CR52","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/j.bbmt.2018.12.068","volume":"25","author":"AJ Kansagra","year":"2019","unstructured":"Kansagra AJ, Frey NV, Bar M, et al. Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European society for blood and marrow transplantation and the American society for blood and marrow transplantation. Biol Blood Marrow Transpl. 2019;25(3):e76\u201385. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.068.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"26","key":"14227_CR53","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u201330.","journal-title":"Blood"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14227-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14227-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14227-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T06:26:26Z","timestamp":1746771986000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14227-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14227"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14227-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. FDA Adverse Event Reporting System is a spontaneous reporting system, the publicly available data are anonymized, and therefore, obtaining consent to participate is not applicable. The present pharmacovigilance study was conducted using a public database of spontaneous reports. Given the use of deidentified data, ethical approval was not considered necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"846"}}